Staphylococcus vaccine (Staphypan) has been proposed as an immunomodulatory therapy in the treatment of Chronic Fatigue Syndrome. It was first used in Sweden with patients who became ill after a 1957 outbreak of Asian flu.
Staphypan is no longer being commercially manufactured. Another staphylococcal toxoid vaccine manufactured by Russian Medgamal is being used by some patients, but it does not contain the same antigens as Staphypan. Its efficacy is unclear but is thought to be less than that of Staphypan.
- Interview with Professor Carl-Gerhard Gottfries, Part 1: Background and Vaccine, YouTube
- A forgotten treatment for fibromyalgia/chronic fatigue syndrome?, CFS Remission blog, January 30, 2016
- YouTube - Interview with Professor Carl-Gerhard Gottfries, Part 1: Background and Vaccine
- IACFS/ME - Immunotherapy of Fibromyalgia and Chronic Fatigue Syndrome by a Staphylococcus Toxoid Vaccine
- Zachrisson, Olof; Regland, Björn; Jahreskog, Marianne; Jonsson, Michael; Kron, Margareta; Gottfries, Carl-Gerhard (2002), "Treatment with staphylococcus toxoid in fibromyalgia/chronic fatigue syndrome--a randomised controlled trial", European Journal of Pain (London, England), 6 (6): 455–466, ISSN 1090-3801, PMID 12413434
- Zachrisson, O.; Colque-Navarro, P.; Gottfries, C. G.; Regland, B.; Möllby, R. (February 2004), "Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement", European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology, 23 (2): 98–105, ISSN 0934-9723, PMID 14735403, doi:10.1007/s10096-003-1062-8
- Reference needed